Chronic lymphocytic leukemia (CLL) expresses the tyrosine kinase receptor ROR1, as do, for example, pancreatic cancer and lung cancer. ROR1 is not found in normal adult cells. ROR1 is essential for the survival of cancer cells and its expression increases with the aggressiveness of the disease. Antibodies have been produced against ROR1, which specifically kill leukemia cells and pancreatic cancer cells. These antibodies kill leukemia cells better than rituximab and ofatumumab, the antibodies that are the standard treatment for CLL. Our antibodies can eliminate leukemia cells in an animal model. We have also produced small chemical molecules, tyrosine kinase inhibitors (TKIs), that specifically recognize ROR1 and kill tumor cells. These drugs have a different mechanism of action than antibodies. We have generated ROR1 TKIs, which can kill leukemia cells more specifically and effectively than fludarabine. They kill 60 times more leukemia cells than normal white blood cells. These ROR TKIs also kill leukemia cells that are resistant to fludarabine. ROR1 TKIs kill pancreatic cancer cells better than gemcitabine. The molecules have promising pharmacological properties. The goal is now to conduct treatment trials in animal models to develop ROR candidates for clinical treatment trials in patients. CLL is a non-curable disease and current treatment options for lung and pancreatic cancer are poor. There is a great need to develop new therapies. ROR1 is a promising structure for developing new targeted therapies against small side effects on normal cells.